Roxadustat
Roxadustat is a pharmaceutical drug with 50 clinical trials. Currently 4 active trials ongoing. Historical success rate of 94.4%.
Success Metrics
Based on 34 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
10
Mid Stage
31
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
91.9%
34 of 37 finished
8.1%
3 ended early
4
trials recruiting
50
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
Effect of Low Doses of Hypoxia-inducible Factor- Prolyl Hydroxylase Enzyme Inhibitor Plus Iron in the Treatment of Anemia in Dialysis-dependent Chronic Kidney Disease Patients
Study of Roxadustat's Effect on Anemia in Patients With Diabetic Kidney Disease
Study of Roxadustat for Reducing the Incidence of Acute Kidney Injury After Coronary Artery Bypass Grafting
Clinical Trials (50)
A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
Effect of Low Doses of Hypoxia-inducible Factor- Prolyl Hydroxylase Enzyme Inhibitor Plus Iron in the Treatment of Anemia in Dialysis-dependent Chronic Kidney Disease Patients
Study of Roxadustat's Effect on Anemia in Patients With Diabetic Kidney Disease
Study of Roxadustat for Reducing the Incidence of Acute Kidney Injury After Coronary Artery Bypass Grafting
Effect of Roxadustat on Heart Failure Patients With Anaemia and Moderate-to-Severe Chronic Kidney Disease
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients
Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia
HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia
Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients
Roxadustat for Bone and Neuropsychiatric Aspects in Hemodialysis Patients
Effect of Perioperative Roxadustat in Elective Lumbar Interbody Fusion Surgery.
Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy
Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa
Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis
A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia
A Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoieses Stimulating Agent (ESA) Treatment
A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation in Healthy Adult Subjects
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 50